Join SFOG and A-Synaptic for an exclusive webinar on May 18th at 2:00 p.m. ET to learn more.
Revolutionary GT4 Transdermal Technology Shows Clinical Potential in Delivering CBD Through the Skin Barriers in Order to Treat Childhood Epilepsy
A-Synaptic has successfully completed an in vitro Franz Cell study showing the capability of its GT4 transdermal technology to move CBD through the skin in clinically meaningful quantities. It is important to note that this test also showed that the 2 top selling US commercial CBD topicals were unable to deliver any measurable amounts of CBD into the bloodstream vs very high delivery by the GT4 transdermal topical.
In addition, A-Synaptic has successfully completed an in vivo human bioavailability study conducted in Canada as authorized by Health Canada. This study has been published in a peer reviewed scientific journal. The study showed the GT4 speed and efficiency in moving clinically meaningful amounts of both CBD and THC through the skin and into systemic circulation. A-Synaptic plans to launch a competing product to the highly successful orally delivered CBD prescription product, Epidiolex. The very positive results of the Franz Cell testing and the recently completed human bioavailability study give A-Synaptic the confidence to believe that its patented GT4 technology will allow them to successfully treat epileptic children with far less drug and without the liver toxicity risks associated with oral delivery of CBD.
For more information please contact Matthew T. Sheridan at Matthew@SpotlightFamilyOffice.com